Robert Horsburgh
Profiles

Charles R Horsburgh, Jr, MD

Professor, Global Health - Boston University School of Public Health

(617) 358-3758
rhorsbu@bu.edu
Crosstown Center
View Full Profile at BUMC

Biography

Dr. Horsburgh has 30 years of experience in public health and medicine. He currently holds faculty positions in the Departments of Epidemiology, Biostatistics, Global Health and Medicine. Dr. Horsburgh teaches courses in the Epidemiology of AIDS, the Epidemiology of Tuberculosis and Vaccine Epidemiology. His research focuses on tuberculosis, nontuberculous mycobacterial infections and opportunistic infections in AIDS. Currently, he is involved in research in Brazil, India, South Africa, Tanzania, Vietnam and the Philippines. He is a member of the Board of Directors of the International Union Against Tuberculosis and Lung Disease (IUATLD) and Chairman of the Steering Committee of RESIST-TB, an international organization dedicated to improving MDR-TB treatment through Clinical Trials and dissemination of best practices (www.resisttb.org).

Other Positions

  • Professor, Epidemiology - Boston University School of Public Health
  • Professor, Biostatistics - Boston University School of Public Health
  • Professor, Medicine - Boston University Chobanian & Avedisian School of Medicine

Education

  • Case Western Reserve University, MD Field of Study: Medicine
  • Yale University, MS Field of Study: Urban Studies
  • Princeton University, AB Field of Study: Architecture

Websites

Classes Taught

  • SPHEP730
  • SPHEP764
  • SPHEP784
  • SPHEP911
  • SPHGH941

Publications

  • Published on 10/6/2025

    Rosen LV, Thielking AM, Dugdale CM, Montepiedra G, Kalk E, Kim S, LaCourse SM, Mathad JS, Freedberg KA, Horsburgh CR, Paltiel AD, Wood R, Ciaranello AL, Reddy KP. Tuberculosis Preventive Treatment for Pregnant People With HIV in South Africa: A Modeling Analysis of Clinical Benefits and Risks. Clin Infect Dis. 2025 Oct 06; 81(3):613-622. PMID: 39544107.

     Read At: PubMed
  • Published on 9/22/2025

    Carwile ME, Prakash Babu S, Cintron C, Dauphinais M, Pan SJ, Thulasingam M, Horsburgh CR, Sarkar S, Hochberg NS, Sabin LL, Flynn D, Kumar B, Sinha P, Singh UB. TB stigma in India: A narrative review of types of stigma, gender differences, and potential interventions. PLOS Glob Public Health. 2025; 5(9):e0005109. PMID: 40982550.

     Read At: PubMed
  • Published on 9/10/2025

    Rao PS, Prakash Babu S, Ezhumalai K, Knudsen S, Ramakrishnan J, Joseph N, Cintron C, Dauphinais MR, Narasimhan PB, Salgame P, Hochberg NS, Hom DL, Heysell SK, Horsburgh CR, Ellner JJ, Sinha P, Sarkar S. Rifampin Exposure in Pregnant and Non-Pregnant Women with Tuberculosis in India. J Infect Dis. 2025 Sep 10. PMID: 40925610.

     Read At: PubMed
  • Published on 9/10/2025

    Sinha P, Karoly M, Padmapriyadarsini C, Paradkar M, Mave V, Gupte N, Gupta A, Dauphinais M, Babu SP, Gaikwad S, Cox SR, Golub J, Cintron C, Thangakunam B, Ezhumalai K, Ponnuraja C, Tornheim JA, Christopher DJ, Viswanathan V, Ellner JJ, Kornfeld H, Horsburgh CR, Bala Yogendra Shivakumar SV, Salgame P, Bollinger RC, Sarkar S, Gupte AN. Contribution of Key Comorbidities to Unfavorable Treatment Outcomes Among Adults With Drug-sensitive Pulmonary TB in India: A Prospective Cohort Analysis. Chest. 2025 Sep 10. PMID: 40939932.

     Read At: PubMed
  • Published on 8/29/2025

    Niemand N, Rooney JA, Malatesta S, Rawoot N, Bouton TC, Ragan EJ, Carney T, White LF, Farhat M, Horsburgh CR, Myers B, Warren RM, Jacobson KR. Contamination rates in serially sampled sputum specimens obtained during tuberculosis treatment to capture culture conversion. Microbiol Spectr. 2025 Aug 29; e0096925. PMID: 40879468.

     Read At: PubMed
  • Published on 8/20/2025

    Sinha P, Bhargava M, Dauphinais MR, Carwile ME, Horsburgh CR, Singh UB, Sarkar S, Bhargava A, Menzies NA. In-kind Nutritional Supplementation for Persons With Drug-susceptible Tuberculosis and Their Household Contacts Would be Cost-effective for Reducing Tuberculosis Incidence and Mortality in Jharkhand, India: A Modeling Study. Clin Infect Dis. 2025 Aug 20. PMID: 40833109.

     Read At: PubMed
  • Published on 8/1/2025

    Hyle EP, Maphosa T, Rangaraj A, Feser M, Singini GC, Shrestha P, Shroufi A, Reddy KP, Matiya E, Dambe R, Talbot VR, Chamanga R, Horsburgh CR, Weinstein MC, Nyirenda RK, Ford N, Tiam A, Phillips A, Freedberg KA. Clinical impact and cost-effectiveness of the WHO-recommended advanced HIV disease package of care. Lancet Glob Health. 2025 Aug; 13(8):e1436-e1447. PMID: 40712615.

     Read At: PubMed
  • Published on 8/1/2025

    Tzelios CA, Malatesta S, Carney T, White LF, Weber SE, Thomson S, Theron D, Myers B, Parry CDH, Warren RM, Horsburgh CR, Farhat MR, Jacobson KR. Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis. Clin Infect Dis. 2025 Aug 01; 81(1):167-175. PMID: 39973802.

     Read At: PubMed
  • Published on 7/30/2025

    Phillips PP, Peloquin CA, Sterling TR, Mitnick CD, Horsburgh CR. Reply to Liao et al.: Optimizing Levofloxacin Dosing for MDR-TB in Low Fat-Free Mass Asian Populations. Am J Respir Crit Care Med. 2025 Jul 30. PMID: 40737625.

     Read At: PubMed
  • Published on 7/14/2025

    Dupuis GN, Dolynska M, Chiang SS, Horsburgh CR, Stagg HR, Rybak NR, Petrenko V, Jenkins HE. Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment. Eur Respir J. 2025 Jul; 66(1). PMID: 40610055.

     Read At: PubMed

View 370 more publications:View Full Profile at BUMC

News & In the Media

View all profiles